Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Canadian Journal of Cardiology

Volumn 32, Issue 7, 2016, Pages 831-841

  Virani, Sean A ^a   Dent, Susan ^b   Brezden Masley, Christine ^c   Clarke, Brian ^d   Davis, Margot K ^a   Jassal, Davinder S ^e   Johnson, Christopher ^f   Lemieux, Julie ^g   Paterson, Ian ^h   Sebag, Igal A ⁱ   Simmons, Christine ^a   Sulpher, Jeffrey ^b   Thain, Kishore ^j   Thavendiranathan, Paaldinesh ^k   Wentzell, Jason R ^l   Wurtele, Nola ^a   Côté, Marc André ^g   Fine, Nowell M ^m   Haddad, Haissam ⁿ   Hayley, Bradley D ^o   Hopkins, Sean ^p   Joy, Anil A ^h   Rayson, Daniel ^q   Stadnick, Ellamae ^r   Straatman, Lynn ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j QUEEN S UNIVERSITY   (Canada)

^k TORONTO GENERAL HOSPITAL   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

^m LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

ⁿ UNIVERSITY OF SASKATCHEWAN   (Canada)

^o MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^p Royal Victoria Hospital Barrie   (Canada)

^q QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^r UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIOTONIC AGENT; CARDIOTOXIN; TROPONIN T;

ARTERY THROMBOSIS; ARTICLE; CANADA; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; ADVERSE EFFECTS; ARRHYTHMIAS, CARDIAC; BLOOD; CINE MAGNETIC RESONANCE IMAGING; CORONARY THROMBOSIS; EARLY DIAGNOSIS; HEART LEFT VENTRICLE FUNCTION; MYOCARDIAL ISCHEMIA; NEOPLASMS; RADIOTHERAPY; THREE DIMENSIONAL ECHOCARDIOGRAPHY;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CARDIOTOXICITY; CARDIOTOXINS; CORONARY THROMBOSIS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; PRIMARY PREVENTION; RADIOTHERAPY; RISK FACTORS; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84975516651     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.02.078     Document Type: Article

References (84)

1. de Moor J.S., Mariotto A.B., Parry C., et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013, 22:561-570.
2. Patnaik J.L., Byers T., DiGuiseppi C., Dabelea D., Denberg T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011, 13:R64.
3. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
4. Daher I.N., Daigle T.R., Bhatia N., Durand J.B. The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J 2012, 39:190-198.
5. McCormack J.P., Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician 2007, 53:1326-1327.
6. Jones L.W., Haykowsky M.J., Swartz J.J., et al. Early breast cancer therapy and myocardial injury. J Am Coll Cardiol 2007, 50:1435-1441.
7. Cardinale D., Bacchiani M., Colombo A., et al. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 2013, 40:186-198.
8. Armstrong G.T., Oeffinger K.C., Chen Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013, 31:3673-3680.
9. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
10. Meachem L.R., Chow E.J., Ness K.K., et al. Cardiovascular risk factors in adult survivors of pediatric cancer - a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2010, 19:170-181.
11. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
12. Smith I., Procter M., Gelber R.D., et al. HERA study team 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
13. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
14. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
15. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
16. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95:1592-1600.
17. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009, 27:127-145.
18. Curigliano G., Cardinale D., Suter T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012, 23(suppl 7):155-166.
19. Nazer B., Humphreys B.D., Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011, 124:1687-1691.
20. Small H.Y., Montezano A.C., Rios F.J., et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014, 30:534-543.
21. Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
22. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
23. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation trial. J Clin Oncol 2009, 27:3312-3318.
24. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
25. Taunk N.K., Haffty B.G., Kostis J.B., Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol 2015, 5:1-8.
26. Jaworski C., Mariani J.A., Wheeler G., Kaye D.M. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013, 61:2319-2328.
27. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.
28. Plana J.C., Galderisi M., Barac A., et al. Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014, 27:911-939.
29. Daher I.N., Kim C., Saleh R.R., et al. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography 2011, 28:1061-1067.
30. Jones A.L., Barlow M., Barrett-Lee P.J., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
31. Jacobs L.D., Salgo I.S., Goonewardena S., et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 2006, 27:460-468.
32. Otterstad J.E., Froeland G., St John Sutton M., Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997, 18:507-513.
33. Thavendiranathan P., Grant A.D., Negishi T., et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013, 61:77-84.
34. Armstrong G.T., Plana J.C., Zhang N., et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012, 30:2876-2884.
35. Yu E.H., Sloggett C.E., Iwanochko R.M., Rakowski H., Siu S.C. Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients. J Am Soc Echocardiogr 2000, 13:216-224.
36. Mulvagh S.L., Rakowski H., Vannan M.A., et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2008, 21:1179-1201.
37. Bellenger N.G., Burgess M.I., Ray S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 2000, 21:1387-1396.
38. Naik M.M., Diamond G.A., Pai T., Soffer A., Siegel R.J. Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol 1995, 25:937-942.
39. Walker J., Bhullar N., Fallah-Rad N., et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010, 28:3429-3436.
40. Fallah-Rad N., Lytwyn M., Fang T., Kirkpatrick I., Jassal D.S. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008, 10:5.
41. Zeglinski M., Ludke A., Jassal D.S., Singal P.K. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol 2011, 16:70-74.
42. Strohm O., Schultz-Menger J., Pilz B., et al. Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. J Magn Reson Imaging 2001, 13:367-371.
43. Thavendiranathan P., Wintersperger B.J., Flamm S.D., Marwick T.H. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 2013, 6:1080-1091.
44. Grothues F., Smith G.C., Moon J.C., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002, 90:29-34.
45. Fallah-Rad N., Walker J.R., Wassef A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant Trastuzumab therapy. J Am Coll Cardiol 2011, 57:2263-2270.
46. Sawaya H., Sebag I.A., Plana J.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012, 5:596-603.
47. Thavendiranathan P., Poulin F., Lim K.D., et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014, 63:2751-2768.
48. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710-715.
49. Sandri M.T., Cardinale D., Zorzino L., et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003, 49:248-252.
50. Horacek J.M., Pudil R., Jebavy L., et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007, 29:309-313.
51. Cardinale D., Colombo A., Torrisi R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28:3910-3916.
52. Ky B., Putt M., Sawaya H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014, 63:809-816.
53. Bosch X., Rovira M., Sitges M., et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the overcome trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013, 61:2355-2362.
54. Negishi K., Negishi T., Haluska B.A., et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014, 15:324-331.
55. Kalam K., Marwick T.H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013, 49:2900-2909.
56. Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 2014, 64:938-945.
57. Pituskin E., Haykowsky M., Mackey J.R., et al. Rationale and design of the multidisciplinary approach to novel therapies in cardiology oncology research trial (MANTICORE 101-breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011, 11:318.
58. Heck S.L., Gulati G., Ree A.H., et al. Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. Cardiology 2012, 123:240-247.
59. Lancellotti P., Nkomo V.T., Badano L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013, 14:721-740.
60. Darby S.C., Ewertz M., McGale P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013, 368:987-998.
61. Mast M.E., van Kempen-Harteveld L., Heijenbrok M.W., et al. Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further?. Radiother Oncol 2013, 108:248-253.
62. Zellars R., Bravo P.E., Tryggestad E., et al. SPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2014, 88:778-785.
63. Harris E.E., Correa C., Hwang W.T., et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, 24:4100-4106.
64. Daskalopoulou S.S., Rabi D.M., Zarnke K.B., et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015, 31:549-568.
65. Skanes A.C., Healey J.S., Cairns J.A., et al. Focussed 2012 Update of the Canadian Cardiovacsular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
66. Ghatalia P., Je Y., Kaymakcalan M.D., et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015, 112:296-305.
67. Bello C.L., Mulay M., Huang X., et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009, 15:7045-7052.
68. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003, 348:1866-1874.
69. Kelly C., Bhuva N., Harrison M., et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013, 49:2303-2310.
70. Saif M.W., Shah M.M., Shah A.R. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009, 8:191-202.
71. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/American College of Cardiology/American Heart Association guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014, 64:2645-2687.
72. Manojlovic N., Babic D., Stojanovic S., et al. Capecitabine cardiotoxicity-case reports and literature review. Hepatogastroenterology 2008, 55:1249-1256.
73. Cianci G., Morelli M.F., Cannita K., et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003, 88:1507-1509.
74. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704.
75. Mancini G.B., Gosselin G., Chow B., et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol 2014, 30:837-849.
76. Welsh R.C., Travers A., Huynh T., Cantor W.J. Canadian Cardiovascular Society Working Group: providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction. Can J Cardiol 2009, 25:25-32.
77. Lancellotti P., Nkomo V.T., Badano L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013, 26:1013-1032.
78. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 22:23-45.
79. Smuder A.J., Kavazis A.N., Min K., Powers S.K. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol 2011, 111:935-942.
80. Jones L, Dolinsky VW, Haykowsky MJ, et al. Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer. Presented at: 102nd Annual Meeting of the American Association of Cancer Research, April 2-6, 2011; Orlando, FL.
81. Seicean S., Seicean A., Alan N., et al. Cardioprotective effect of β-adrenoreceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013, 6:420-426.
82. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
83. Yeh E.T. Onco-cardiology: the time has come. Tex Heart Inst J 2011, 38:246-247.
84. Howlett J.G., Chan M., Ezekowitz J.A., et al. The Canadian Cardiovascular Society Heart Failure Companion: bridging guidelines to your practice. Can J Cardiol 2016, 32:296-310.